Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests

Name of Advisory Committee Member: Bruce Roth, M.D.

Committee: Oncologic Drugs Advisory Committee (ODAC)

Meeting Date: July 13, 2017 Morning Session

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item: Biologics license application (BLA) 761028 for ABP 215, a proposed biosimilar to Genentech/Roche’s AVASTIN (bevacizumab), submitted by Amgen Inc. The proposed indications/uses for this product are:(1) For the first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-fluorouracil-based chemotherapy; (2) in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line ABP 215-containing regimen; (3) for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer in combination with carboplatin and paclitaxel; (4) for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent; (5) for the treatment of metastatic renal cell carcinoma in combination with interferon alfa; and (6) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of persistent, recurrent, or metastatic carcinoma of the cervix, I may be considered for participation in the advisory committee meeting described above.

<table>
<thead>
<tr>
<th>Type of Interest</th>
<th>Nature</th>
<th>Magnitude</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Personal/Immediate Family</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td>II. Other Imputed Interests</td>
<td>Employer’s research contract (8) (4), Competing firm</td>
<td>$0 – $50,000 total</td>
</tr>
</tbody>
</table>

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

__________/S/__________________  ________6/22/2017______________
Signature  Date